Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.

Olson BM, Gamat M, Seliski J, Sawicki T, Jeffery J, Ellis L, Drake CG, Weichert J, McNeel DG.

Cancer Immunol Res. 2017 Dec;5(12):1074-1085. doi: 10.1158/2326-6066.CIR-16-0390. Epub 2017 Oct 19.

2.

Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination.

Johnson LE, Olson BM, McNeel DG.

J Immunother Cancer. 2017 Jul 18;5(1):56. doi: 10.1186/s40425-017-0260-3.

3.

Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.

Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC, Elemento O, Novak J, Thornley TB, Asara JM, Montaser L, Timmons JJ, Morgan TM, Wang Y, Levantini E, Clohessy JG, Kelly K, Pandolfi PP, Rosenblatt JM, Avigan DE, Ye H, Karp JM, Signoretti S, Balk SP, Cantley LC.

Cancer Discov. 2017 Jul;7(7):750-765. doi: 10.1158/2159-8290.CD-16-0778. Epub 2017 Mar 8.

4.

Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).

Olson BM, Bradley ES, Sawicki T, Zhong W, Ranheim EA, Bloom JE, Colluru VT, Johnson LE, Rekoske BT, Eickhoff JC, McNeel DG.

Prostate. 2017 May;77(7):812-821. doi: 10.1002/pros.23321. Epub 2017 Feb 9.

5.

Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses.

Rekoske BT, Olson BM, McNeel DG.

Oncoimmunology. 2016 Mar 28;5(6):e1165377. doi: 10.1080/2162402X.2016.1165377. eCollection 2016 Jun.

6.

PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.

Rekoske BT, Smith HA, Olson BM, Maricque BB, McNeel DG.

Cancer Immunol Res. 2015 Aug;3(8):946-55. doi: 10.1158/2326-6066.CIR-14-0206. Epub 2015 Jun 3.

7.

Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer.

McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM.

Clin Cancer Res. 2014 Jul 15;20(14):3692-704. doi: 10.1158/1078-0432.CCR-14-0169. Epub 2014 May 21.

8.

Preclinical and clinical development of DNA vaccines for prostate cancer.

Colluru VT, Johnson LE, Olson BM, McNeel DG.

Urol Oncol. 2016 Apr;34(4):193-204. doi: 10.1016/j.urolonc.2013.09.014. Epub 2013 Dec 12. Review.

9.

Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments.

Johnson LE, Becker JT, Dubovsky JA, Olson BM, McNeel DG.

Chin Clin Oncol. 2013 Mar 1;2(1). doi: 10.3978/j.issn.2304-3865.2012.11.06.

10.

Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance.

Olson BM, Sullivan JA, Burlingham WJ.

Front Immunol. 2013 Oct 18;4:315. doi: 10.3389/fimmu.2013.00315. Review.

11.

Monitoring regulatory immune responses in tumor immunotherapy clinical trials.

Olson BM, McNeel DG.

Front Oncol. 2013 May 6;3:109. doi: 10.3389/fonc.2013.00109. eCollection 2013.

12.

Vaccination using peptides spanning the SYT-SSX tumor-specific translocation.

Bloom JE, McNeel DG, Olson BM.

Expert Rev Vaccines. 2012 Dec;11(12):1401-4. doi: 10.1586/erv.12.122.

13.

Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence.

Olson BM, McNeel DG.

Expert Rev Vaccines. 2012 Nov;11(11):1315-7. doi: 10.1586/erv.12.107.

14.

Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.

Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ, McNeel DG.

J Immunol. 2012 Dec 15;189(12):5590-601. doi: 10.4049/jimmunol.1201744. Epub 2012 Nov 14.

15.

DNA Vaccines for Prostate Cancer.

McNeel DG, Becker JT, Johnson LE, Olson BM.

Curr Cancer Ther Rev. 2012 Nov 1;8(4):254-263.

16.

The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer.

Olson BM, Johnson LE, McNeel DG.

Cancer Immunol Immunother. 2013 Mar;62(3):585-96. doi: 10.1007/s00262-012-1363-9. Epub 2012 Oct 30.

17.

CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.

Olson BM, McNeel DG.

Cancer Immunol Immunother. 2011 Jun;60(6):781-92. doi: 10.1007/s00262-011-0987-5. Epub 2011 Feb 25.

18.

Sipuleucel-T: immunotherapy for advanced prostate cancer.

Olson BM, McNeel DG.

Open Access J Urol. 2011 May 3;3:49-60. doi: 10.2147/OAJU.S13069. Review.

19.

DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.

Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG.

J Immunother. 2010 Jul-Aug;33(6):639-47. doi: 10.1097/CJI.0b013e3181dda23e.

20.

HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.

Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG.

Cancer Immunol Immunother. 2010 Jun;59(6):943-53. doi: 10.1007/s00262-010-0820-6. Epub 2010 Feb 6.

Supplemental Content

Loading ...
Support Center